Adaptimmune Therapeutics PLC - ADR
General ticker "ADAP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $166.7M
Adaptimmune Therapeutics PLC - ADR does not follow the US Stock Market performance with the rate: -9.1%.
Estimated limits based on current volatility of 3.1%: low 0.58$, high 0.62$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.47$, 1.44$]
- 2024-12-30 to 2025-12-30 estimated range: [0.78$, 2.07$]
Financial Metrics affecting the ADAP estimates:
- Negative: Non-GAAP EPS, $ of -0.64 <= 0.10
- Negative: Operating profit margin, % of -69.86 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -58.17 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ADAP quotes
Long-term ADAP plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $6.15MM | $27.15MM | $60.28MM |
| Operating Expenses | $168.40MM | $191.11MM | $200.02MM |
| Operating Income | $-162.25MM | $-163.97MM | $-139.74MM |
| Non-Operating Income | $4.95MM | $1.01MM | $27.21MM |
| R&D Expense | $111.09MM | $127.73MM | $126.51MM |
| Income(Loss) | $-157.30MM | $-162.96MM | $-112.53MM |
| Taxes | $0.79MM | $2.50MM | $1.34MM |
| Profit(Loss) | $-158.09MM | $-165.46MM | $-113.87MM |
| Stockholders Equity | $205.96MM | $81.88MM | $39.51MM |
| Inventory | $0.75MM | $1.28MM | $0.00MM |
| Assets | $469.55MM | $328.92MM | $282.62MM |
| Operating Cash Flow | $10.73MM | $-141.77MM | $-140.88MM |
| Capital expenditure | $8.78MM | $29.74MM | $4.88MM |
| Investing Cash Flow | $75.80MM | $89.14MM | $176.54MM |
| Financing Cash Flow | $3.29MM | $12.87MM | $0.88MM |
| Earnings Per Share* | $-1.01 | $-1.03 | $-0.57 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.